MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    7,8- Dihydroxyflavone prevents 3-NitropropionicAcid (3-NP)-induced Striatal Toxicity by Modulating the TrkB receptor and Microglial Activation Pathway

    S. Ahmed, M. Kwatra, VGM. Naidu (Kamrup, India)

    Objective: Hungtion’s disease (HD) is an autosomal governing neurodegenerative disorder caused by production of mutant hungtingtin(Htt) protein followed by death of the GABAergic neurons in…
  • 2019 International Congress

    MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates

    J. Higgins, B. Blits, L. Spronck, A. Valles-Sanchez, M. Evers, S. van Deventer, P. Konstantinova, M. de Haan (Lexington, MA, USA)

    Objective: To assess the effects of intra-striatal administration of a huntingtin protein (HTT) lowering gene therapy in macaca fascicularis non-human primates (NHP). Background: The aggregation…
  • 2019 International Congress

    Multimodal characterization of the visual network in Huntington’s disease

    O. Odish, S. Gregory, I. Mayer, J.. Mills, E. Johnson, R. Scahill, J. Rothwell, G. Rees, J. Long, S. Tabrizi, R. Roos, M. Orth (Leiden, Netherlands)

    Objective: To examine the relationship between structural organization, functional processing and task performance of the visual system in a cohort of Huntington’s disease (HD) gene-mutation…
  • 2019 International Congress

    Using functional status to aid interpretation of cUHDRS scores in patients with Huntington’s disease

    D. Trundell, G. Palermo, J. Long, B. Leavitt, S. Schobel, S. Tabrizi (Welwyn Garden City, United Kingdom)

    Objective: To enhance understanding of the composite Unified Huntington’s Disease Rating Scale (cUHDRS) scoring by linking to established measures of meaningful daily function and independence…
  • 2019 International Congress

    Systematic review of Mucuna Pruriens as a treatment for Parkinson’s disease

    TH. Boonmongkol, O. Phokaewvarangkul, S. Vimolmangkang, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To conduct a systematic review of the therapeutic evidence for Mucuna Pruriens (MP) in the treatment of Parkinson’s disease (PD). Background: MP or Velvet bean is a…
  • 2019 International Congress

    Laboratory Performance of the DopaFuse® Delivery System

    R. Draper, J. Harmon, A. Heller, B. Heller, E. Heller, C. King, T. Lau, P. Plante, J. Spiridigliozzi (Austin, TX, USA)

    Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…
  • 2019 International Congress

    Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease

    G. Hatipoglu, S. Ozkaynak (Antalya, Turkey)

    Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…
  • 2019 International Congress

    Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism

    A. Jain, S. Jain (Sagar, India)

    Objective: Parkinson’s disease (PD) is a common neurodegenerative disease characterized by motor symptoms of tremor, rigidity, bradykinesia, and postural instability. Growing evidence indicates that resveratrol…
  • 2019 International Congress

    Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.

    A. Lees, J. Ferreira, O. Rascol, W. Poewe, F. Stocchi, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…
  • 2019 International Congress

    Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program

    K. Marek, A. Siderowf, C. Coffey, T. Foroud, V. Arnedo, E. Flagg, S. Chowdhury, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

    Objective: The overall objective of the Path to Prevention (P2P) initiative is to identify clinical, imaging, and biologic markers of progression during the prodromal phase…
  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley